{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002306","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.435754+00:00","generated_at":"2026-06-05T04:41:01.632757+00:00","sec_items":["2.01","2.04","1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Coherus completes CIMERLI ophthalmology sale to Sandoz for $170M cash; repays $175M debt","bullets":["Closed sale of CIMERLI franchise to Sandoz for upfront $170M cash plus $17.8M for inventory and prepaid manufacturing assets.","Proceeds used to partially repay $175M of $250M term loan principal on or before April 1, 2024, plus $6.8M premium and makewhole.","Transaction sharpens strategic focus on oncology; CIMERLI BLA, sales team, and commercial software transferred.","Pro forma net loss for nine months ended Sep 30, 2023 would have been $196M versus historical $158M; loss per share $1.97 vs $1.79.","Cash and equivalents pro forma $77.7M after debt paydown and disposition adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002306","json":"https://secwatch.observer/filing/0001558370-24-002306.json","markdown":"https://secwatch.observer/filing/0001558370-24-002306.md","text":"https://secwatch.observer/filing/0001558370-24-002306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024002306/0001558370-24-002306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024002306/chrs-20240301x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:41:01.632757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8d072a3c33ad7573aa856787d7c03d457162ba2","claim":"Coherus Oncology, Inc. amended term loan with Biopharma Credit PLC, BPCR Limited Partnership, Biopharma Credit Investments V (MASTER) LP.","evidence_excerpt":"on February 5, 2024, the Company, as borrower and on behalf of itself and certain of its subsidiaries, entered into a Consent, Partial Release and Third Amendment to Loan Agreement (the “Consent and Amendment”) with Biopharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (the “Collateral Agent”), BPCR Limited Partnership, a limited partnership established under the laws of England and Wales, as a lender (“BPCR”), and Biopharma Credit Investments V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a lender, and together with as BPCR, each, a “Lender” and collectively, the “Lenders”), pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Existing Loan Agreement and the other loan documents in connection therewith, and the partie","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024002306/0001558370-24-002306-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Counterparty","value":"Biopharma Credit PLC, BPCR Limited Partnership, Biopharma Credit Investments V (MASTER) LP"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"4c0f38ec96b5aa60e5536116cff64ef987f97a66","claim":"Coherus Oncology, Inc. completed a disposition involving Sandoz Inc. for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets (closed 2024-03-01).","evidence_excerpt":"On March 1, 2024, the Company completed the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Purchaser (the “Disposition”) for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024002306/0001558370-24-002306-index.htm","confidence":0.98,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Sandoz Inc."},{"label":"Consideration","value":"upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets"},{"label":"Closing","value":"2024-03-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}